{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:17:08Z","timestamp":1759936628420},"reference-count":270,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.bbcan.2012.03.011","type":"journal-article","created":{"date-parts":[[2012,3,31]],"date-time":"2012-03-31T07:30:29Z","timestamp":1333179029000},"page":"89-102","source":"Crossref","is-referenced-by-count":18,"title":["Genetics and epigenetics of cutaneous malignant melanoma: A concert out of tune"],"prefix":"10.1016","volume":"1826","author":[{"given":"Karin","family":"van den Hurk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanneke E.C.","family":"Niessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Veeck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost J.","family":"van den Oord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurice A.M.","family":"van Steensel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"zur Hausen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manon","family":"van Engeland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique J.L.","family":"Winnepenninckx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2012.03.011_bb0005","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1038\/sj.onc.1206460","article-title":"Development of melanocyte precursors from the vertebrate neural crest","volume":"22","author":"Dupin","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0010","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1535-6108(02)00161-7","article-title":"Focus on melanoma","volume":"2","author":"Houghton","year":"2002","journal-title":"Cancer Cell"},{"issue":"Suppl. 6","key":"10.1016\/j.bbcan.2012.03.011_bb0015","doi-asserted-by":"crossref","first-page":"vi1","DOI":"10.1093\/annonc\/mdp252","article-title":"Epidemiology of invasive cutaneous melanoma","volume":"20","author":"MacKie","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0020","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0025","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/1097-0142(197312)32:6<1446::AID-CNCR2820320623>3.0.CO;2-8","article-title":"The classification of malignant melanoma and its histologic reporting","volume":"32","author":"McGovern","year":"1973","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0030","first-page":"705","article-title":"The histogenesis and biologic behavior of primary human malignant melanomas of the skin","volume":"29","author":"Clark","year":"1969","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0035","doi-asserted-by":"crossref","first-page":"e18257","DOI":"10.1371\/journal.pone.0018257","article-title":"A melanoma molecular disease model","volume":"6","author":"Vidwans","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0040","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.molonc.2011.03.002","article-title":"Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care","volume":"5","author":"Scolyer","year":"2011","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0045","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0046-8177(84)80310-X","article-title":"A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma","volume":"15","author":"Clark","year":"1984","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0050","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMra052166","article-title":"Melanoma","volume":"355","author":"Miller","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0055","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0060","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nature05661","article-title":"Melanoma biology and new targeted therapy","volume":"445","author":"Gray-Schopfer","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0065","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1200\/JCO.2006.06.0483","article-title":"Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group","volume":"24","author":"Bedikian","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0070","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1200\/JCO.2004.04.165","article-title":"Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study","volume":"22","author":"Avril","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0075","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","article-title":"Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma","volume":"17","author":"Chapman","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0080","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ejca.2004.04.030","article-title":"Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?","volume":"40","author":"Eggermont","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0085","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0090","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.bbcan.2012.03.011_bb0095","first-page":"S11","article-title":"High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update","volume":"6","author":"Atkins","year":"2000","journal-title":"Cancer J. Sci. Am."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0100","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1001\/jama.1994.03510360033032","article-title":"Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2","volume":"271","author":"Rosenberg","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0105","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1200\/JCO.2008.16.3121","article-title":"Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma","volume":"27","author":"Pectasides","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0110","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0115","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/1078-0432.CCR-1103-3","article-title":"A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma","volume":"10","author":"Kirkwood","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0120","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)61033-8","article-title":"Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial","volume":"372","author":"Eggermont","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0125","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0130","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0135","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nrd3579","article-title":"Vemurafenib","volume":"10","author":"Flaherty","year":"2011","journal-title":"Nat. Rev."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0140","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0145","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":"KIT as a therapeutic target in metastatic melanoma","volume":"305","author":"Carvajal","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0150","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0155","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3233\/CBM-2011-0164","article-title":"The molecular pathology of cutaneous melanoma","volume":"9","author":"Bogenrieder","year":"2011","journal-title":"Cancer Biomark."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0160","doi-asserted-by":"crossref","first-page":"9790","DOI":"10.1074\/jbc.M212929200","article-title":"Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling","volume":"278","author":"Govindarajan","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0165","first-page":"3728","article-title":"Mitogen-actived protein kinase activation is an early event in melanoma progression","volume":"8","author":"Cohen","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0170","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.1158\/1078-0432.CCR-08-0575","article-title":"KIT gene mutations and copy number in melanoma subtypes","volume":"14","author":"Beadling","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0175","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0180","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/path.1424","article-title":"Expression of AP-2alpha, c-kit, and cleaved caspase-6 and -3 in naevi and malignant melanomas of the skin. A possible role for caspases in melanoma progression?","volume":"201","author":"Woenckhaus","year":"2003","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0185","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.humpath.2006.01.003","article-title":"BRAF and c-kit gene copy number in mutation-positive malignant melanoma","volume":"37","author":"Willmore-Payne","year":"2006","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0190","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.humpath.2005.03.015","article-title":"Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis","volume":"36","author":"Willmore-Payne","year":"2005","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0195","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1128\/MCB.9.7.3114","article-title":"N-ras mutations in human cutaneous melanoma from sun-exposed body sites","volume":"9","author":"van't Veer","year":"1989","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0200","first-page":"1363","article-title":"Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype","volume":"4","author":"Albino","year":"1989","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0205","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/1523-1747.ep12371783","article-title":"Ras mutations in human melanoma: a marker of malignant progression","volume":"102","author":"Ball","year":"1994","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0210","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0215","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10555-005-5865-1","article-title":"The role of B-RAF in melanoma","volume":"24","author":"Gray-Schopfer","year":"2005","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0220","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ng1054","article-title":"High frequency of BRAF mutations in nevi","volume":"33","author":"Pollock","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0225","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.jid.5700490","article-title":"Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations","volume":"127","author":"Bauer","year":"2007","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0230","doi-asserted-by":"crossref","first-page":"463184","DOI":"10.1155\/2011\/463184","article-title":"Molecular nevogenesis","volume":"2011","author":"Ross","year":"2011","journal-title":"Dermatol. Res. Pract."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0235","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/jnci\/djg123","article-title":"Determinants of BRAF mutations in primary melanomas","volume":"95","author":"Maldonado","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0240","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nature03890","article-title":"BRAFE600-associated senescence-like cell cycle arrest of human naevi","volume":"436","author":"Michaloglou","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0245","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/jnci\/89.10.697","article-title":"Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma","volume":"89","author":"Platz","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0250","first-page":"987","article-title":"Genomic structure, expression and mutational analysis of the P15 (MTS2) gene","volume":"11","author":"Stone","year":"1995","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0255","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1038\/sj.onc.1201470","article-title":"Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds","volume":"15","author":"Flores","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0260","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s004030050286","article-title":"Mutations of p16 and p15 tumor suppressor genes and replication errors contribute independently to the pathogenesis of sporadic malignant melanoma","volume":"290","author":"Matsumura","year":"1998","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0265","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ng0994-22","article-title":"Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus","volume":"8","author":"Kamb","year":"1994","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0270","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/ng0994-15","article-title":"Germline p16 mutations in familial melanoma","volume":"8","author":"Hussussian","year":"1994","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0275","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1038\/sj.onc.1206461","article-title":"The INK4a\/ARF locus and melanoma","volume":"22","author":"Sharpless","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0280","doi-asserted-by":"crossref","first-page":"9818","DOI":"10.1158\/0008-5472.CAN-06-0494","article-title":"High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL","volume":"66","author":"Goldstein","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0285","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/gcc.20518","article-title":"Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas","volume":"47","author":"Helsing","year":"2008","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0290","first-page":"2170","article-title":"Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization","volume":"58","author":"Bastian","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0295","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0300","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/gcc.20310","article-title":"Amplification of CDK4 and MDM2 in malignant melanoma","volume":"45","author":"Muthusamy","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0305","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/gcc.2870120208","article-title":"A genetic model of melanoma tumorigenesis based on allelic losses","volume":"12","author":"Walker","year":"1995","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0310","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/gcc.2870080307","article-title":"Chromosome 10 allelic loss in malignant melanoma","volume":"8","author":"Isshiki","year":"1993","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0315","first-page":"1649","article-title":"Chromosome 9 deletion in sporadic and familial melanomas in vivo","volume":"9","author":"Isshiki","year":"1994","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0320","first-page":"3111","article-title":"Loss of heterozygosity for 10q22\u201310qter in malignant melanoma progression","volume":"54","author":"Herbst","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0325","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1038\/sj.onc.1200203","article-title":"Prognostic significance of allelic losses in primary melanoma","volume":"16","author":"Healy","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0330","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1038\/sj.onc.1210252","article-title":"Genomic profiling of malignant melanoma using tiling-resolution arrayCGH","volume":"26","author":"Jonsson","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0335","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nature03664","article-title":"Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma","volume":"436","author":"Garraway","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0340","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jmoldx.2011.01.011","article-title":"Copy number gains in 11q13 and 8q24 [corrected] are highly linked to prognosis in cutaneous malignant melanoma","volume":"13","author":"Gerami","year":"2011","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0345","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1038\/sj.onc.1201881","article-title":"Identification of PTEN\/MMAC1 alterations in uncultured melanomas and melanoma cell lines","volume":"16","author":"Tsao","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0350","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1038\/sj.onc.1206451","article-title":"PTEN signaling pathways in melanoma","volume":"22","author":"Wu","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0355","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1158\/0008-5472.CAN-04-1399","article-title":"Deregulated Akt3 activity promotes development of malignant melanoma","volume":"64","author":"Stahl","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0360","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.0022-202X.2004.22243.x","article-title":"Genetic interaction between NRAS and BRAF mutations and PTEN\/MMAC1 inactivation in melanoma","volume":"122","author":"Tsao","year":"2004","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0365","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","article-title":"Targeting RAS signalling pathways in cancer therapy","volume":"3","author":"Downward","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0370","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1101\/gad.8.22.2770","article-title":"microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family","volume":"8","author":"Hemesath","year":"1994","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0375","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0092-8674(02)00762-6","article-title":"Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability","volume":"109","author":"McGill","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0380","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1083\/jcb.200410115","article-title":"MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A","volume":"168","author":"Loercher","year":"2005","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0385","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/nature03269","article-title":"Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression","volume":"433","author":"Carreira","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0390","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ccr.2004.10.014","article-title":"Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF","volume":"6","author":"Du","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0395","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1755-148X.2009.00578.x","article-title":"Frequent mutations in the MITF pathway in melanoma","volume":"22","author":"Cronin","year":"2009","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0400","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/nature10539","article-title":"A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma","volume":"480","author":"Bertolotto","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0405","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature10630","article-title":"A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma","volume":"480","author":"Yokoyama","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0410","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1083\/jcb.200505059","article-title":"Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation","volume":"170","author":"Wellbrock","year":"2005","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0415","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1101\/gad.14.14.1712","article-title":"Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage","volume":"14","author":"Goding","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0420","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0002-9440(10)63657-7","article-title":"MLANA\/MART1 and SILV\/PMEL17\/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma","volume":"163","author":"Du","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0425","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1158\/0008-5472.CAN-03-2440","article-title":"Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma","volume":"64","author":"Miller","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0430","first-page":"441","article-title":"Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas","volume":"63","author":"Takeuchi","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0435","first-page":"1515","article-title":"Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis","volume":"58","author":"Duncan","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0440","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1083\/jcb.200202049","article-title":"Beta-catenin-induced melanoma growth requires the downstream target microphthalmia-associated transcription factor","volume":"158","author":"Widlund","year":"2002","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0445","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1073\/pnas.96.10.5522","article-title":"The cyclin D1 gene is a target of the beta-catenin\/LEF-1 pathway","volume":"96","author":"Shtutman","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0450","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2174\/138920111794295710","article-title":"Network of WNT and other regulatory signaling cascades in pluripotent stem cells and cancer stem cells","volume":"12","author":"Katoh","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0455","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/j.1365-2133.2007.08246.x","article-title":"Involvement of E-cadherin, beta-catenin, Cdc42 and CXCR4 in the progression and prognosis of cutaneous melanoma","volume":"157","author":"Tucci","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0460","first-page":"188","article-title":"Shifts in cadherin profiles between human normal melanocytes and melanomas","volume":"1","author":"Hsu","year":"1996","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0465","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1158\/1078-0432.CCR-06-1820","article-title":"Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues","volume":"13","author":"Jaeger","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0470","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra072067","article-title":"Epigenetics in cancer","volume":"358","author":"Esteller","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0475","doi-asserted-by":"crossref","first-page":"388","DOI":"10.4161\/epi.6.3.14056","article-title":"Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma","volume":"6","author":"Nguyen","year":"2011","journal-title":"Epigenetics"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0480","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.bbrc.2009.07.093","article-title":"An essential role for DNA methyltransferase 3a in melanoma tumorigenesis","volume":"387","author":"Deng","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0485","doi-asserted-by":"crossref","DOI":"10.4161\/cc.11.2.18707","article-title":"The BRAFV600E causes widespread alterations in gene methylation in the genome of melanoma cells","volume":"11","author":"Hou","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0490","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1053\/j.seminoncol.2005.07.001","article-title":"Aberrant DNA methylation in cutaneous malignancies","volume":"32","author":"van Doorn","year":"2005","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0495","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/00002371-200201000-00002","article-title":"Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma","volume":"25","author":"Sigalotti","year":"2002","journal-title":"J. Immunother."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0500","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/j.1349-7006.2004.tb03184.x","article-title":"Promoter methylation profiling of 30 genes in human malignant melanoma","volume":"95","author":"Furuta","year":"2004","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0505","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrc1669","article-title":"Cancer\/testis antigens, gametogenesis and cancer","volume":"5","author":"Simpson","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0510","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S1044-579X(02)00060-3","article-title":"The novel BORIS+CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer","volume":"12","author":"Klenova","year":"2002","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0515","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrg1655","article-title":"DNA methylation and human disease","volume":"6","author":"Robertson","year":"2005","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0520","doi-asserted-by":"crossref","first-page":"7751","DOI":"10.1158\/0008-5472.CAN-05-0858","article-title":"Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes","volume":"65","author":"Vatolin","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0525","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/ijc.23140","article-title":"Expression of BORIS in melanoma: lack of association with MAGE-A1 activation","volume":"122","author":"Kholmanskikh","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0530","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1600-0749.2007.00367.x","article-title":"Epigenetic events in malignant melanoma","volume":"20","author":"Rothhammer","year":"2007","journal-title":"Pigment Cell Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0535","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/107327480901600302","article-title":"Epigenetics in human melanoma","volume":"16","author":"Howell","year":"2009","journal-title":"Cancer Control"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0540","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1755-148X.2008.00534.x","article-title":"Epigenetic marks in melanoma","volume":"22","author":"Richards","year":"2009","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0545","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/CMR.0b013e328338a35a","article-title":"Aberrant DNA methylation in malignant melanoma","volume":"20","author":"Schinke","year":"2010","journal-title":"Melanoma Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0550","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1479-5876-8-56","article-title":"Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies","volume":"8","author":"Sigalotti","year":"2010","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0555","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1056\/NEJMra023075","article-title":"Gene silencing in cancer in association with promoter hypermethylation","volume":"349","author":"Herman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0560","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1038\/sj.onc.1207505","article-title":"Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients","volume":"23","author":"Hoon","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0565","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1755-148X.2008.00484.x","article-title":"Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling","volume":"21","author":"Liu","year":"2008","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0570","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1158\/1078-0432.CCR-08-1361","article-title":"CpG island methylator phenotype predicts progression of malignant melanoma","volume":"15","author":"Tanemura","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0575","doi-asserted-by":"crossref","first-page":"9351","DOI":"10.1200\/JCO.2005.02.9876","article-title":"Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy","volume":"23","author":"Mori","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0580","first-page":"1639","article-title":"Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma","volume":"63","author":"Spugnardi","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0585","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/jid.2009.226","article-title":"Methylation of PTEN as a prognostic factor in malignant melanoma of the skin","volume":"130","author":"Lahtz","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0590","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/sj.jid.5700005","article-title":"Promoter hypermethylation of the O(6)-methylguanine DNA methyltransferase gene and microsatellite instability in metastatic melanoma","volume":"126","author":"Kohonen-Corish","year":"2006","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0595","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/sj.jid.5700073","article-title":"Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma","volume":"126","author":"Marini","year":"2006","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0600","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2007.14.5292","article-title":"Phase II study of extended-dose temozolomide in patients with melanoma","volume":"26","author":"Rietschel","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0605","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1158\/0008-5472.CAN-06-0801","article-title":"Estrogen receptor-alpha methylation predicts melanoma progression","volume":"66","author":"Mori","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0610","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/CMR.0b013e32833d32a6","article-title":"Metallothionein 1E is methylated in malignant melanoma and increases sensitivity to cisplatin-induced apoptosis","volume":"20","author":"Faller","year":"2010","journal-title":"Melanoma Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0615","doi-asserted-by":"crossref","first-page":"8681","DOI":"10.1073\/pnas.96.15.8681","article-title":"CpG island methylator phenotype in colorectal cancer","volume":"96","author":"Toyota","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0620","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/nrc1507","article-title":"CpG island methylator phenotype in cancer","volume":"4","author":"Issa","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0625","first-page":"77","article-title":"The CpG island methylator phenotype in colorectal cancer: Progress and problems","volume":"1825","author":"Hughes","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0630","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/carcin\/bgi152","article-title":"Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies","volume":"26","author":"Gallagher","year":"2005","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0635","doi-asserted-by":"crossref","first-page":"11187","DOI":"10.1158\/0008-5472.CAN-06-1274","article-title":"Epigenetic silencing of novel tumor suppressors in malignant melanoma","volume":"66","author":"Muthusamy","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0640","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ijc.22637","article-title":"Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas","volume":"121","author":"Nobeyama","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0645","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/gcc.20615","article-title":"Identification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma","volume":"48","author":"Bonazzi","year":"2009","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0650","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/CMR.0b013e328344a003","article-title":"Use of integrative epigenetic and cytogenetic analyses to identify novel tumor-suppressor genes in malignant melanoma","volume":"21","author":"Mithani","year":"2011","journal-title":"Melanoma Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0655","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1158\/0008-5472.CAN-06-0157","article-title":"Silencing of peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas","volume":"66","author":"Furuta","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0660","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1101\/gr.091447.109","article-title":"Genome-wide screen of promoter methylation identifies novel markers in melanoma","volume":"19","author":"Koga","year":"2009","journal-title":"Genome Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0665","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1755-148X.2011.00828.x","article-title":"DNA-methylation profiling distinguishes malignant melanomas from benign nevi","volume":"24","author":"Conway","year":"2011","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0670","doi-asserted-by":"crossref","first-page":"e26121","DOI":"10.1371\/journal.pone.0026121","article-title":"Cross-platform array screening identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as genes frequently silenced by methylation in melanoma","volume":"6","author":"Bonazzi","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0675","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/ng.298","article-title":"The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores","volume":"41","author":"Irizarry","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0680","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nature09165","article-title":"Conserved role of intragenic DNA methylation in regulating alternative promoters","volume":"466","author":"Maunakea","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0685","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/bjc.2011.550","article-title":"Intragenic DNA methylation: implications of this epigenetic mechanism for cancer research","volume":"106","author":"Shenker","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0690","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1158\/1078-0432.CCR-10-3394","article-title":"Analysis of promoter CpG island hypermethylation in cancer: location, location, location!","volume":"17","author":"van Vlodrop","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0695","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0092-8674(01)00616-X","article-title":"microRNAs: tiny regulators with great potential","volume":"107","author":"Ambros","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0700","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0705","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrg1379","article-title":"MicroRNAs: small RNAs with a big role in gene regulation","volume":"5","author":"He","year":"2004","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0710","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1016-8478(23)13130-X","article-title":"Small RNAs: classification, biogenesis, and function","volume":"19","author":"Kim","year":"2005","journal-title":"Mol. Cells"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0715","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/sj.bjc.6605204","article-title":"Role of miRNAs in the progression of malignant melanoma","volume":"101","author":"Mueller","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0720","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/CMR.0b013e32834f6fbb","article-title":"MicroRNA regulation of melanoma progression","volume":"22","author":"Bonazzi","year":"2012","journal-title":"Melanoma Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0725","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1755-148X.2010.00734.x","article-title":"The evolving concept of \u2018melano-miRs\u2019-microRNAs in melanomagenesis","volume":"23","author":"Mueller","year":"2010","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0730","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1038\/jid.2008.452","article-title":"miRNA expression profiling in melanocytes and melanoma cell lines reveals miRNAs associated with formation and progression of malignant melanoma","volume":"129","author":"Mueller","year":"2009","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0735","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/jid.2010.63","article-title":"MicroRNA expression profiles associated with mutational status and survival in malignant melanoma","volume":"130","author":"Caramuta","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0740","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.2353\/ajpath.2010.091061","article-title":"MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma","volume":"176","author":"Chen","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0745","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/CMR.0b013e32833e32a1","article-title":"Downregulation of miR-125b in metastatic cutaneous malignant melanoma","volume":"20","author":"Glud","year":"2010","journal-title":"Melanoma Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0750","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/1471-2407-10-262","article-title":"High-throughput miRNA profiling of human melanoma blood samples","volume":"10","author":"Leidinger","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0755","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1158\/0008-5472.CAN-09-4512","article-title":"Signatures of microRNAs and selected microRNA target genes in human melanoma","volume":"70","author":"Philippidou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0760","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1158\/1078-0432.CCR-09-2721","article-title":"Melanoma MicroRNA signature predicts post-recurrence survival","volume":"16","author":"Segura","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0765","doi-asserted-by":"crossref","first-page":"e9685","DOI":"10.1371\/journal.pone.0009685","article-title":"Characterization of the melanoma miRNAome by deep sequencing","volume":"5","author":"Stark","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0770","doi-asserted-by":"crossref","first-page":"16606","DOI":"10.1074\/jbc.M111.227611","article-title":"miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein","volume":"286","author":"Dar","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0775","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.4161\/cc.10.11.15777","article-title":"MicroRNA signatures differentiate melanoma subtypes","volume":"10","author":"Chan","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0780","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/bjc.2011.568","article-title":"Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors","volume":"106","author":"Xu","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0785","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1684\/ejd.2011.1210","article-title":"Immunohistochemical expression patterns of the microRNA-processing enzyme Dicer in cutaneous malignant melanomas, benign melanocytic nevi and dysplastic melanocytic nevi","volume":"21","author":"Sand","year":"2011","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0790","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1158\/0008-5472.CAN-07-2912","article-title":"MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines","volume":"68","author":"Bemis","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0795","doi-asserted-by":"crossref","first-page":"e11574","DOI":"10.1371\/journal.pone.0011574","article-title":"miR-148 regulates Mitf in melanoma cells","volume":"5","author":"Haflidadottir","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0800","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1073\/pnas.0808263106","article-title":"Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor","volume":"106","author":"Segura","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0805","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1101\/gad.1706508","article-title":"Chromatin structure analyses identify miRNA promoters","volume":"22","author":"Ozsolak","year":"2008","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0810","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.tcb.2008.07.007","article-title":"The let-7 family of microRNAs","volume":"18","author":"Roush","year":"2008","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0815","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/cr.2008.45","article-title":"MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth","volume":"18","author":"Schultz","year":"2008","journal-title":"Cell Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0820","doi-asserted-by":"crossref","first-page":"6698","DOI":"10.1038\/onc.2008.282","article-title":"Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma","volume":"27","author":"Muller","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0825","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1600-0625.2010.01163.x","article-title":"The microRNA molecular signature of atypic and common acquired melanocytic nevi: differential expression of miR-125b and let-7c","volume":"20","author":"Holst","year":"2011","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0830","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/CMR.0b013e328345333b","article-title":"MicroRNA miR-125b induces senescence in human melanoma cells","volume":"21","author":"Glud","year":"2011","journal-title":"Melanoma Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0835","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/onc.2011.345","article-title":"A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth","volume":"31","author":"Streicher","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0840","doi-asserted-by":"crossref","first-page":"13556","DOI":"10.1073\/pnas.0803055105","article-title":"A microRNA DNA methylation signature for human cancer metastasis","volume":"105","author":"Lujambio","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0845","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.4161\/cc.7.16.6533","article-title":"Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer","volume":"7","author":"Lodygin","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0850","doi-asserted-by":"crossref","first-page":"e24922","DOI":"10.1371\/journal.pone.0024922","article-title":"Epigenetic regulation of microRNA genes and the role of miR-34b in cell invasion and motility in human melanoma","volume":"6","author":"Mazar","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0855","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/j.febslet.2011.06.025","article-title":"Epigenetic regulation of microRNA-375 and its role in melanoma development in humans","volume":"585","author":"Mazar","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0860","doi-asserted-by":"crossref","first-page":"10128","DOI":"10.1158\/0008-5472.CAN-08-2148","article-title":"MicroRNAs impair MET-mediated invasive growth","volume":"68","author":"Migliore","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0865","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/ncb1998","article-title":"The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs","volume":"11","author":"Wellner","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0870","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/ncb1722","article-title":"The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1","volume":"10","author":"Gregory","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0875","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1101\/gad.1640608","article-title":"The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2","volume":"22","author":"Park","year":"2008","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0880","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1007\/s00018-009-8750-1","article-title":"The role of microRNAs in metastasis and epithelial\u2013mesenchymal transition","volume":"66","author":"Bracken","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0885","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013176","article-title":"MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion","volume":"5","author":"Elson-Schwab","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0890","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/path.2964","article-title":"MicroRNA-9 up-regulates E-cadherin through inhibition of NF-kappaB1-Snail1 pathway in melanoma","volume":"226","author":"Liu","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0895","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrg2521","article-title":"Long non-coding RNAs: insights into functions","volume":"10","author":"Mercer","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0900","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1158\/0008-5472.CAN-06-2004","article-title":"Characterization of a germ-line deletion, including the entire INK4\/ARF locus, in a melanoma\u2013neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF","volume":"67","author":"Pasmant","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0905","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/ng.407","article-title":"Genome-wide association study identifies five susceptibility loci for glioma","volume":"41","author":"Shete","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0910","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/ng.412","article-title":"New common variants affecting susceptibility to basal cell carcinoma","volume":"41","author":"Stacey","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0915","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/ng.601","article-title":"A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci","volume":"42","author":"Bei","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0920","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1096\/fj.10-172452","article-title":"ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS","volume":"25","author":"Pasmant","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0925","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1111\/j.1365-2605.2011.01162.x","article-title":"Genome-wide association studies provide new insights into the genetic basis of testicular germ-cell tumour","volume":"34","author":"Turnbull","year":"2011","journal-title":"Int. J. Androl."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0930","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1158\/0008-5472.CAN-10-4460","article-title":"The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion","volume":"71","author":"Khaitan","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0935","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2007.02.005","article-title":"Chromatin modifications and their function","volume":"128","author":"Kouzarides","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0940","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1158\/1541-7786.MCR-10-0511","article-title":"EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21\/CDKN1A expression","volume":"9","author":"Fan","year":"2011","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0945","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/35051606","article-title":"Inactivation of the apoptosis effector Apaf-1 in malignant melanoma","volume":"409","author":"Soengas","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0950","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/1535-7163.425.3.4","article-title":"The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells","volume":"3","author":"Zhang","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0955","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0006-2952(03)00509-4","article-title":"The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis","volume":"66","author":"Zhang","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0960","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1023\/B:APPT.0000038036.31271.50","article-title":"Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors","volume":"9","author":"Facchetti","year":"2004","journal-title":"Apoptosis"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0965","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/nrc1991","article-title":"Polycomb silencers control cell fate, development and cancer","volume":"6","author":"Sparmann","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0970","first-page":"151","article-title":"Polycomb repression: from cellular memory to cellular proliferation and cancer","volume":"1602","author":"Jacobs","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0975","doi-asserted-by":"crossref","first-page":"396","DOI":"10.4161\/cc.3.4.773","article-title":"Polycomb group proteins in cell cycle progression and cancer","volume":"3","author":"Pasini","year":"2004","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0980","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1600-0560.2006.00678.x","article-title":"Expression of Polycomb group protein EZH2 in nevi and melanoma","volume":"34","author":"McHugh","year":"2007","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0985","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2005.01.5180","article-title":"EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast","volume":"24","author":"Bachmann","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb0990","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/16476","article-title":"The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus","volume":"397","author":"Jacobs","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2012.03.011_bb0995","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/modpathol.2008.17","article-title":"Loss of BMI-1 expression is associated with clinical progress of malignant melanoma","volume":"21","author":"Bachmann","year":"2008","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1000","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1101\/gad.511109","article-title":"Histone demethylase JMJD3 contributes to epigenetic control of INK4a\/ARF by oncogenic RAS","volume":"23","author":"Barradas","year":"2009","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1005","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1101\/gad.510809","article-title":"The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A\u2013ARF locus in response to oncogene- and stress-induced senescence","volume":"23","author":"Agger","year":"2009","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1010","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/sj.jid.5700324","article-title":"Re-expression of the retinoblastoma-binding protein 2-homolog 1 reveals tumor-suppressive functions in highly metastatic melanoma cells","volume":"126","author":"Roesch","year":"2006","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1015","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/ijc.23211","article-title":"RBP2-H1\/JARID1B is a transcriptional regulator with a tumor suppressive potential in melanoma cells","volume":"122","author":"Roesch","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb1020","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/modpathol.3800413","article-title":"Retinoblastoma-binding protein 2-homolog 1: a retinoblastoma-binding protein downregulated in malignant melanomas","volume":"18","author":"Roesch","year":"2005","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1025","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.cell.2010.04.020","article-title":"A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth","volume":"141","author":"Roesch","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2012.03.011_bb1030","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrm1945","article-title":"Chromatin remodelling: the industrial revolution of DNA around histones","volume":"7","author":"Saha","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1035","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nrc3068","article-title":"SWI\/SNF nucleosome remodellers and cancer","volume":"11","author":"Wilson","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb1040","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1476-4598-8-4","article-title":"The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a","volume":"8","author":"Becker","year":"2009","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb1045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/onc.2009.304","article-title":"Heterogeneous SWI\/SNF chromatin remodeling complexes promote expression of microphthalmia-associated transcription factor target genes in melanoma","volume":"29","author":"Keenen","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2012.03.011_bb1050","doi-asserted-by":"crossref","first-page":"20233","DOI":"10.1074\/jbc.M512052200","article-title":"The microphthalmia-associated transcription factor requires SWI\/SNF enzymes to activate melanocyte-specific genes","volume":"281","author":"de la Serna","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1055","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbrc.2010.01.048","article-title":"SWI\/SNF chromatin remodeling complex is critical for the expression of microphthalmia-associated transcription factor in melanoma cells","volume":"392","author":"Vachtenheim","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1060","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1474-9726.2007.00308.x","article-title":"Dynamic assembly of chromatin complexes during cellular senescence: implications for the growth arrest of human melanocytic nevi","volume":"6","author":"Bandyopadhyay","year":"2007","journal-title":"Aging Cell"},{"key":"10.1016\/j.bbcan.2012.03.011_bb1065","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cell.2007.12.032","article-title":"Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7","volume":"132","author":"Wajapeyee","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2012.03.011_bb1070","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4161\/epi.5.6.12315","article-title":"SWItching on the transcriptional circuitry in melanoma","volume":"5","author":"Vinod Saladi","year":"2010","journal-title":"Epigenetics"},{"key":"10.1016\/j.bbcan.2012.03.011_bb1075","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0092-8674(94)90405-7","article-title":"The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrest","volume":"79","author":"Dunaief","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2012.03.011_bb1080","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0092-8674(00)80625-X","article-title":"Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI\/SNF and Rb-hSWI\/SNF","volume":"101","author":"Zhang","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2012.03.011_bb1085","doi-asserted-by":"crossref","first-page":"17745","DOI":"10.1073\/pnas.0509014102","article-title":"Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation","volume":"102","author":"Isakoff","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1090","doi-asserted-by":"crossref","first-page":"11268","DOI":"10.1073\/pnas.94.21.11268","article-title":"RB and hbrm cooperate to repress the activation functions of E2F1","volume":"94","author":"Trouche","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1095","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1093\/jnci\/djn157","article-title":"Frequent p16-independent inactivation of p14ARF in human melanoma","volume":"100","author":"Freedberg","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0002-9440(10)64174-0","article-title":"Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase","volume":"161","author":"Straume","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1105","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1093\/jnci\/djn156","article-title":"Tumor suppression for ARFicionados: the relative contributions of p16INK4a and p14ARF in melanoma","volume":"100","author":"Peters","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1110","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/sj.bjc.6603283","article-title":"Cellular senescence in naevi and immortalisation in melanoma: a role for p16?","volume":"95","author":"Gray-Schopfer","year":"2006","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb1115","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/ng1972","article-title":"A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing","volume":"39","author":"Ohm","year":"2007","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1120","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1101\/gad.381706","article-title":"Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions","volume":"20","author":"Bracken","year":"2006","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1125","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/ncb1077","article-title":"Polycomb CBX7 has a unifying role in cellular lifespan","volume":"6","author":"Gil","year":"2004","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1130","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1038\/sj.emboj.7601632","article-title":"Bypass of senescence by the Polycomb group protein CBX8 through direct binding to the INK4A-ARF locus","volume":"26","author":"Dietrich","year":"2007","journal-title":"EMBO J."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1135","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1073\/pnas.0434312100","article-title":"Rnf2 (Ring1b) deficiency causes gastrulation arrest and cell cycle inhibition","volume":"100","author":"Voncken","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1140","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1101\/gad.415507","article-title":"The Polycomb group proteins bind throughout the INK4A\u2013ARF locus and are disassociated in senescent cells","volume":"21","author":"Bracken","year":"2007","journal-title":"Genes Dev."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1145","doi-asserted-by":"crossref","first-page":"11667","DOI":"10.1073\/pnas.0904715106","article-title":"Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression","volume":"106","author":"Khalil","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1150","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1158\/0008-5472.CAN-08-3114","article-title":"The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the Polycomb group protein EZH2","volume":"69","author":"Friedman","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1155","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1126\/science.1165395","article-title":"Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer","volume":"322","author":"Varambally","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.bbcan.2012.03.011_bb1160","doi-asserted-by":"crossref","first-page":"e1864","DOI":"10.1371\/journal.pone.0001864","article-title":"p16(INK4a) translation suppressed by miR-24","volume":"3","author":"Lal","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2012.03.011_bb1165","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1074\/jbc.M309333200","article-title":"P16INK4a is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells","volume":"279","author":"Oruetxebarria","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1170","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1128\/MCB.02019-07","article-title":"SWI\/SNF mediates Polycomb eviction and epigenetic reprogramming of the INK4b\u2013ARF\u2013INK4a locus","volume":"28","author":"Kia","year":"2008","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1175","doi-asserted-by":"crossref","first-page":"6344","DOI":"10.1158\/1078-0432.CCR-06-2682","article-title":"Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response","volume":"13","author":"Ugurel","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1180","first-page":"2881","article-title":"Loss of PTEN promotes tumor development in malignant melanoma","volume":"63","author":"Stahl","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1185","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.1158\/0008-5472.CAN-06-0384","article-title":"Epigenetic silencing of the PTEN gene in melanoma","volume":"66","author":"Mirmohammadsadegh","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1190","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1158\/1078-0432.CCR-08-3172","article-title":"Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma","volume":"15","author":"Kitago","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1195","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1001\/archderm.139.6.816","article-title":"Identification of novel deletion loci at 1p36 and 9p22-21 in melanocytic dysplastic nevi and cutaneous malignant melanomas","volume":"139","author":"Hussein","year":"2003","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1200","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00008390-200302000-00006","article-title":"Microsatellite analysis at 1p36.3 in malignant melanoma of the skin: fine mapping in search of a possible tumour suppressor gene region","volume":"13","author":"Poetsch","year":"2003","journal-title":"Melanoma Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1205","first-page":"1567","article-title":"Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients","volume":"59","author":"Fujiwara","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1210","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1158\/1078-0432.CCR-06-0883","article-title":"Phase I trial of sequential low-dose 5-aza-2\u2032-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma","volume":"12","author":"Gollob","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1215","first-page":"3200","article-title":"Cyclin D1 is a candidate oncogene in cutaneous melanoma","volume":"62","author":"Sauter","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1220","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/(SICI)1097-0215(19971021)74:5<535::AID-IJC10>3.0.CO;2-5","article-title":"Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma","volume":"74","author":"Straume","year":"1997","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb1225","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/jid.2011.380","article-title":"RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi","volume":"132","author":"Helmbold","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1230","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1038\/sj.onc.1207647","article-title":"Genetic and epigenetic alterations of the APC gene in malignant melanoma","volume":"23","author":"Worm","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2012.03.011_bb1235","first-page":"5336","article-title":"Low frequency of p16\/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors","volume":"57","author":"Gonzalgo","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1240","doi-asserted-by":"crossref","first-page":"410","DOI":"10.4161\/epi.5.5.11929","article-title":"Id1 overexpression is independent of repression and epigenetic silencing of tumor suppressor genes in melanoma","volume":"5","author":"Healey","year":"2010","journal-title":"Epigenetics"},{"key":"10.1016\/j.bbcan.2012.03.011_bb1245","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1038\/sj.onc.1203891","article-title":"Aberrant p27Kip1 promoter methylation in malignant melanoma","volume":"19","author":"Worm","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2012.03.011_bb1250","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/ijc.11376","article-title":"ASC\/TMS1, a caspase-1 activating adaptor, is downregulated by aberrant methylation in human melanoma","volume":"107","author":"Guan","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb1255","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/carcin\/bgr138","article-title":"Epigenetic deregulation of TCF21 inhibits metastasis suppressor KISS1 in metastatic melanoma","volume":"32","author":"Arab","year":"2011","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bbcan.2012.03.011_bb1260","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1002\/ijc.24960","article-title":"MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma","volume":"126","author":"Satzger","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb1265","first-page":"393","article-title":"Altered expression of selected microRNAs in melanoma: antiproliferative and proapoptotic activity of miRNA-155","volume":"35","author":"Levati","year":"2009","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1270","doi-asserted-by":"crossref","first-page":"e18936","DOI":"10.1371\/journal.pone.0018936","article-title":"Regulation of cancer aggressive features in melanoma cells by microRNAs","volume":"6","author":"Greenberg","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2012.03.011_bb1275","doi-asserted-by":"crossref","unstructured":"L. Jiang, X. Lv, J. Li, X. Li,W. Li, Y. Li, The status of microRNA-21 expression and its 1584 clinical significance in human cutaneous malignant melanoma, Acta Histochem. [Electronic publication ahead of print], doi:10.1016\/j.acthis.2011.11.001.","DOI":"10.1016\/j.acthis.2011.11.001"},{"key":"10.1016\/j.bbcan.2012.03.011_bb1280","doi-asserted-by":"crossref","first-page":"39172","DOI":"10.1074\/jbc.M111.285098","article-title":"MicroRNA miR-21 regulates the metastatic behavior of B16 melanoma cells","volume":"286","author":"Yang","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1285","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/bjc.2011.288","article-title":"miR-21 and miR-155 are associated with mitotic activity and lesion depth of borderline melanocytic lesions","volume":"105","author":"Grignol","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb1290","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ccr.2011.05.027","article-title":"miR-30b\/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis","volume":"20","author":"Gaziel-Sovran","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2012.03.011_bb1295","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7150\/ijbs.7.133","article-title":"MicroRNA-137 targets carboxyl-terminal binding protein 1 in melanoma cell lines","volume":"7","author":"Deng","year":"2011","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1300","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1755-148X.2011.00857.x","article-title":"MicroRNA-155 targets the SKI gene in human melanoma cell lines","volume":"24","author":"Levati","year":"2011","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1305","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1158\/0008-5472.CAN-06-2698","article-title":"Characterization of microRNA expression levels and their biological correlates in human cancer cell lines","volume":"67","author":"Gaur","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1310","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/ijc.25768","article-title":"MicroRNA miR-196a controls melanoma-associated genes by regulating HOX-C8 expression","volume":"129","author":"Mueller","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbcan.2012.03.011_bb1315","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1007\/s00018-010-0394-7","article-title":"MicroRNA miR-196a is a central regulator of HOX-B7 and BMP4 expression in malignant melanoma","volume":"67","author":"Braig","year":"2010","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1320","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1755-148X.2011.00849.x","article-title":"Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor","volume":"24","author":"Boyle","year":"2011","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1325","first-page":"665","article-title":"Downregulation of microRNA-211 is involved in expression of preferentially expressed antigen of melanoma in melanoma cells","volume":"39","author":"Sakurai","year":"2011","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1330","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/emboj.2011.102","article-title":"microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C","volume":"30","author":"Penna","year":"2011","journal-title":"EMBO J."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1335","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.bbrc.2008.12.152","article-title":"MicroRNA-dependent regulation of cKit in cutaneous melanoma","volume":"379","author":"Igoucheva","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1340","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1586\/14737140.8.11.1759","article-title":"MicroRNA-221 and -222 pathway controls melanoma progression","volume":"8","author":"Felicetti","year":"2008","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1345","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1158\/0008-5472.CAN-07-2538","article-title":"The promyelocytic leukemia zinc finger-microRNA-221\/-222 pathway controls melanoma progression through multiple oncogenic mechanisms","volume":"68","author":"Felicetti","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2012.03.011_bb1350","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jdermsci.2010.12.010","article-title":"The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker","volume":"61","author":"Kanemaru","year":"2011","journal-title":"J. Dermatol. Sci."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X1200025X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X1200025X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T13:00:08Z","timestamp":1713790808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X1200025X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":270,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0304419X1200025X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2012.03.011","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}